Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Taletrectinib for ROS1+ NSCLC
Pooled, international, open-label, single-arm, phase II studies (TRUST-I and TRUST-II) Advanced or metastatic ROS1+ NSCLC, TKI-naïve or previously treated (crizotinib/entrectinib)
New Reference: Trastuzumab Deruxtecan for her2+ Gastric Cancer
International, randomized, open-label, phase 3 trial (DESTINY-Gastric04) HER2-positive metastatic gastric or GE junction adenoCa after trastuzumab-based therapy Trastuzumab deruxte
New Protocol: Venetoclax with Decitabine for AML Induction in Fit Patients
Phase 2b, multicenter, randomized, open-label, noninferiority trial (NCT05177731) Young (18–59 yrs), newly diagnosed, fit AML patients eligible for intensive chemotherapy Venetoc
New Reference: Vepdegestrant for ER+ Breast Cancer
Phase 3, open-label, randomized trial (VERITAC-2) ER-positive, HER2-negative advanced breast cancer pts previously treated with CDK4/6 inhibitor and endocrine therapy Vepdegestrant
New Protocol: Zanubrutinib with Venetoclax for Untreated CLL
Phase 2, nonrandomized cohort within SEQUOIA trial (SEQUOIA Arm D) Treatment-naïve CLL/SLL patients with or without TP53-aberrant disease Zanubrutinib from cycle 1 + venetoclax ra
New Reference: Zongertinib for her2 Mutated NSCLC
Multicohort, open-label, phase 1a–1b trial (Beamion LUNG-1, NCT04886804) Previously treated advanced or metastatic HER2-mutant NSCLC Zongertinib 120 mg daily (selected dose) in p
New Protocol: TFOX for Advanced Gastric Cancer
Phase 3, open-label, multicenter randomized trial (PRODIGE 51- FFCD-GASTFOX) Pts with previously untreated advanced HER2-negative gastric/GEJ adenocarcinoma TFOX (docetaxel + oxali
New Reference: RiTUXimab alone for Follicular Lymphoma
Randomised, open-label, phase 3 trial (NCT00112931) Advanced stage (II–IV), asymptomatic, low tumour burden follicular lymphoma (grade 1–3a) Watchful waiting vs. rituximab indu
New Reference: Neoadjuvant FOLFOX + Panitumumab for Colon Cancer
Randomised, open-label, embedded phase II trial (FOxTROT) Resectable, locally advanced colon adenocarcinoma (T3-4, N0-2, M0) in RAS/BRAF-wildtype patients Neoadjuvant FOLFOX + pani
